The Importance of Pfizer's Drug Pipeline Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Source: Fool
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine propelled revenue from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financials.
- Declining Stock Trend: Although Pfizer's revenue remains higher than pre-pandemic levels, its stock price has dropped approximately 29% over the past five years, reflecting market concerns about future growth potential, especially amid waning vaccine demand.
- Acquisition Strategy: Pfizer's acquisition of Metsera, which has no market drugs but weight-loss candidates in trials, and Seagen in 2023 to enhance its oncology business, demonstrates the company's proactive efforts to identify new growth drivers.
- Importance of Drug Pipeline: Pfizer's situation underscores the critical importance of a robust drug pipeline, as failure to adapt when patents expire or drug demand declines can lead to significant shareholder losses, emphasizing the necessity for ongoing innovation and R&D.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.950
Low
24.00
Averages
28.56
High
35.00
Current: 25.950
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Faces Competitive Pressure in GLP-1 Drug Market
- Intensifying Market Competition: Pfizer has not launched a GLP-1 weight-loss drug, resulting in a stock price decline of over 50% since its 2021 peak, with its market visibility significantly diminished as competitors like Eli Lilly and Novo Nordisk excel.
- Patent Expiration Risks: The company faces multiple significant patent expirations in the coming years, which are expected to impact both revenue and profit, compelling Pfizer to increase R&D spending to mitigate potential losses.
- Strategic Adaptability: After dropping its own GLP-1 drug, Pfizer quickly acquired a startup with a promising GLP-1 candidate and inked a distribution deal with a Chinese firm, demonstrating its ability to adapt to market changes, potentially laying the groundwork for future competition.
- Long-Term Investment Potential: Despite current challenges, Pfizer offers a high dividend yield of 6.7%, with management committed to supporting this dividend, suggesting that long-term investors may find a valuable turnaround opportunity in Pfizer.
See More
Pfizer Faces Challenges but Remains Underrated
- Poor Market Performance: Pfizer, with a market cap of $140 billion, has seen its stock price drop over 50% since its 2021 peak, reflecting market concerns about its future, particularly as competitors gain attention with their GLP-1 weight-loss drugs.
- Increased R&D Investment: Despite not launching a GLP-1 drug and facing significant patent expirations, Pfizer is heavily investing in its drug pipeline, particularly in oncology, vaccines, and migraine treatments, demonstrating its commitment to future growth.
- Strategic Adaptability: After dropping its own GLP-1 drug, Pfizer quickly acquired a promising startup and secured a distribution deal with a Chinese company, showcasing its agility and strong market adaptability.
- Long-term Investment Value: Pfizer offers a high dividend yield of 6.7%, with management focused on supporting this dividend during challenging times, suggesting that long-term investors may reap substantial rewards as Pfizer navigates its turnaround.
See More
Merck's KEYTRUDA Combination Therapy Recommended for Bladder Cancer Approval
- Therapy Recommendation: The European Medicines Agency's Committee has adopted a positive opinion recommending Merck's KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer, marking a significant advancement in clinical application.
- Clinical Trial Basis: This recommendation is based on results from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas, demonstrating the efficacy and safety of this combination therapy for specific patient populations.
- Market Authorization Review: The recommendation will be reviewed by the European Commission for marketing authorization in the EU, Iceland, Liechtenstein, and Norway, with a final decision expected by Q3 2026, potentially impacting future market access.
- Positive Stock Market Reaction: In pre-market trading on the NYSE, Merck shares rose by 2.57% to $118.85, reflecting market optimism regarding the approval prospects of this therapy.
See More
WHO Warns of Potential Worsening of Ebola Outbreak
- Severity of Outbreak: The WHO reports that the ongoing Ebola outbreak in East Africa has resulted in over 130 deaths, with suspected cases rising to 600 in the Democratic Republic of the Congo and Uganda, indicating the severity and potential spread of the epidemic.
- Public Health Emergency: WHO Director-General Tedros declared the Ebola outbreak a Public Health Emergency of International Concern, marking the highest level of global health alert, reflecting the urgency and potential threat to global health posed by the epidemic.
- Vaccine Development Progress: Although no vaccines are currently available for the Bundibugyo strain, WHO advisors stated that two candidate vaccines are under study, demonstrating scientific efforts to combat the outbreak and future hope for prevention.
- International Travel Restrictions: The U.S. CDC has imposed travel restrictions from three African countries to prevent the spread of the Ebola virus, indicating the international community's heightened awareness and response measures to the outbreak.
See More
Pfizer Initiates Phase 3 Trial for 25-Valent Pneumococcal Vaccine
- Vaccine Trial Progress: Pfizer has announced the initiation of a Phase 3 clinical trial for its 25-valent pneumococcal vaccine, PF-07872412, which outperformed the existing 20-valent vaccine, Prevnar 20, in mid-stage trials, indicating its potential advantages in pediatric applications.
- Significant Immune Response: Data from the Phase 2 trial showed that 25vPnC elicited an immune response nearly 15 times higher against serotype 3 in healthy infants compared to the FDA-approved Prevnar 20, providing strong support for the vaccine's efficacy.
- Good Safety Profile: Pfizer noted that the investigational vaccine was well-tolerated with no new safety concerns, establishing a solid foundation for its use in children and enhancing market confidence.
- Future Development Plans: Pfizer is also planning to develop a fifth-generation pneumococcal vaccine aimed at covering 35 serotypes, with its adult vaccine expected to enter clinical development by the end of this year, demonstrating the company's ongoing innovation and market expansion potential in the vaccine sector.
See More
Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials
- Strong Phase 2 Results: Pfizer's 25-valent pneumococcal conjugate vaccine demonstrated an 8.8-fold higher immune response against serotype 3 compared to PREVNAR 20 after Dose 3, and a 15-fold increase after Dose 4, indicating significant potential for enhanced protection in children.
- Phase 3 Pediatric Program Launch: Following encouraging Phase 2 data, Pfizer initiated its pivotal Phase 3 pediatric trial in May 2026, aiming to enroll 2,400 children randomized to receive either 25vPnC or PCV20, which will further validate the vaccine's efficacy and safety.
- Expanded Vaccine Coverage: The candidate vaccine is designed to cover 25 serotypes, including five additional strains not included in PREVNAR 20, potentially broadening protection to about 90% of disease-causing serotypes in children under five, significantly enhancing public health defense.
- Advancement of Adult Vaccine Candidate: Pfizer is also moving forward with a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, with clinical development expected to begin by the end of 2026, aiming to further enhance immunogenicity against critical strains, showcasing the company's ongoing innovation in vaccine development.
See More
Pfizer Faces Competitive Pressure in GLP-1 Drug Market
- Intensifying Market Competition: Pfizer has not launched a GLP-1 weight-loss drug, resulting in a stock price decline of over 50% since its 2021 peak, with its market visibility significantly diminished as competitors like Eli Lilly and Novo Nordisk excel.
- Patent Expiration Risks: The company faces multiple significant patent expirations in the coming years, which are expected to impact both revenue and profit, compelling Pfizer to increase R&D spending to mitigate potential losses.
- Strategic Adaptability: After dropping its own GLP-1 drug, Pfizer quickly acquired a startup with a promising GLP-1 candidate and inked a distribution deal with a Chinese firm, demonstrating its ability to adapt to market changes, potentially laying the groundwork for future competition.
- Long-Term Investment Potential: Despite current challenges, Pfizer offers a high dividend yield of 6.7%, with management committed to supporting this dividend, suggesting that long-term investors may find a valuable turnaround opportunity in Pfizer.
See More
Pfizer Faces Challenges but Remains Underrated
- Poor Market Performance: Pfizer, with a market cap of $140 billion, has seen its stock price drop over 50% since its 2021 peak, reflecting market concerns about its future, particularly as competitors gain attention with their GLP-1 weight-loss drugs.
- Increased R&D Investment: Despite not launching a GLP-1 drug and facing significant patent expirations, Pfizer is heavily investing in its drug pipeline, particularly in oncology, vaccines, and migraine treatments, demonstrating its commitment to future growth.
- Strategic Adaptability: After dropping its own GLP-1 drug, Pfizer quickly acquired a promising startup and secured a distribution deal with a Chinese company, showcasing its agility and strong market adaptability.
- Long-term Investment Value: Pfizer offers a high dividend yield of 6.7%, with management focused on supporting this dividend during challenging times, suggesting that long-term investors may reap substantial rewards as Pfizer navigates its turnaround.
See More
Merck's KEYTRUDA Combination Therapy Recommended for Bladder Cancer Approval
- Therapy Recommendation: The European Medicines Agency's Committee has adopted a positive opinion recommending Merck's KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer, marking a significant advancement in clinical application.
- Clinical Trial Basis: This recommendation is based on results from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas, demonstrating the efficacy and safety of this combination therapy for specific patient populations.
- Market Authorization Review: The recommendation will be reviewed by the European Commission for marketing authorization in the EU, Iceland, Liechtenstein, and Norway, with a final decision expected by Q3 2026, potentially impacting future market access.
- Positive Stock Market Reaction: In pre-market trading on the NYSE, Merck shares rose by 2.57% to $118.85, reflecting market optimism regarding the approval prospects of this therapy.
See More
WHO Warns of Potential Worsening of Ebola Outbreak
- Severity of Outbreak: The WHO reports that the ongoing Ebola outbreak in East Africa has resulted in over 130 deaths, with suspected cases rising to 600 in the Democratic Republic of the Congo and Uganda, indicating the severity and potential spread of the epidemic.
- Public Health Emergency: WHO Director-General Tedros declared the Ebola outbreak a Public Health Emergency of International Concern, marking the highest level of global health alert, reflecting the urgency and potential threat to global health posed by the epidemic.
- Vaccine Development Progress: Although no vaccines are currently available for the Bundibugyo strain, WHO advisors stated that two candidate vaccines are under study, demonstrating scientific efforts to combat the outbreak and future hope for prevention.
- International Travel Restrictions: The U.S. CDC has imposed travel restrictions from three African countries to prevent the spread of the Ebola virus, indicating the international community's heightened awareness and response measures to the outbreak.
See More
Pfizer Initiates Phase 3 Trial for 25-Valent Pneumococcal Vaccine
- Vaccine Trial Progress: Pfizer has announced the initiation of a Phase 3 clinical trial for its 25-valent pneumococcal vaccine, PF-07872412, which outperformed the existing 20-valent vaccine, Prevnar 20, in mid-stage trials, indicating its potential advantages in pediatric applications.
- Significant Immune Response: Data from the Phase 2 trial showed that 25vPnC elicited an immune response nearly 15 times higher against serotype 3 in healthy infants compared to the FDA-approved Prevnar 20, providing strong support for the vaccine's efficacy.
- Good Safety Profile: Pfizer noted that the investigational vaccine was well-tolerated with no new safety concerns, establishing a solid foundation for its use in children and enhancing market confidence.
- Future Development Plans: Pfizer is also planning to develop a fifth-generation pneumococcal vaccine aimed at covering 35 serotypes, with its adult vaccine expected to enter clinical development by the end of this year, demonstrating the company's ongoing innovation and market expansion potential in the vaccine sector.
See More
Pfizer Advances 25-Valent Pneumococcal Vaccine to Phase 3 Trials
- Strong Phase 2 Results: Pfizer's 25-valent pneumococcal conjugate vaccine demonstrated an 8.8-fold higher immune response against serotype 3 compared to PREVNAR 20 after Dose 3, and a 15-fold increase after Dose 4, indicating significant potential for enhanced protection in children.
- Phase 3 Pediatric Program Launch: Following encouraging Phase 2 data, Pfizer initiated its pivotal Phase 3 pediatric trial in May 2026, aiming to enroll 2,400 children randomized to receive either 25vPnC or PCV20, which will further validate the vaccine's efficacy and safety.
- Expanded Vaccine Coverage: The candidate vaccine is designed to cover 25 serotypes, including five additional strains not included in PREVNAR 20, potentially broadening protection to about 90% of disease-causing serotypes in children under five, significantly enhancing public health defense.
- Advancement of Adult Vaccine Candidate: Pfizer is also moving forward with a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, with clinical development expected to begin by the end of 2026, aiming to further enhance immunogenicity against critical strains, showcasing the company's ongoing innovation in vaccine development.
See More
